Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 568 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced May 21, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions
Losartan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Interventions
Velocity pAVF System
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Riverside, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Fabry Disease, Proteinuria
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of Liver
Interventions
21.15.GPC3-CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
172
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 11:07 PM EDT
Conditions
End Stage Renal Disease, Arteriovenous Fistula, Arteriovenous Graft
Interventions
Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)
Interventions
DCR-PHXC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Acute Kidney Injury, Chronic Kidney Diseases, Renal Dialysis
Interventions
CARPEDIEM
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Autosomal Dominant Polycystic Kidney
Interventions
High Water Intake
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Louisville, Kentucky • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
Conditions
Kidney, Polycystic, Autosomal Dominant
Interventions
Water
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced May 21, 2026, 11:07 PM EDT
Conditions
End-stage Renal Disease
Interventions
PROPATEN, Standard Graft
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
Interventions
Enoblituzumab
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
1 Year to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced May 21, 2026, 11:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
Conditions
Acute Kidney Injury (AKI), Postnatal AKI
Interventions
NIRS Monitoring
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Fabry Disease
Interventions
Iohexol
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years to 25 Years · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
La Jolla, California • Decatur, Georgia • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced May 21, 2026, 11:07 PM EDT
Conditions
Chronic Kidney Diseases, Bladder Dysfunction, Bladder Absence, Posterior Urethral Valve, Neurogenic Bladder, Bladder Exstrophy, Bladder Outlet Obstruction, Failure, Kidney, Transplant
Interventions
Concomitant Renal and Urinary Bladder Allograft Transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 11:07 PM EDT